

HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) --- Annual/Unscheduled Follow-Up ---

SURVIVAL STATUS

Date of follow-up: ____/ __/ __ (*YYYY/MM/DD*) (if died: date of death, if lost to follow up: date last seen)

Survival status:

Alive

Dead

Lost to follow-up

Main cause of death:

(check only one main cause)

Relapse or progression/persistent disease	
Secondary malignancy	
CT-related	Select treatment related cause: (select all that apply) Graft versus Host Disease Non-infectious complication Infectious complication:
☐ HCT-related	(select all that apply)
GT-related	Viral infection
IST-related	 Parasitic infection Infection with unknown pathogen
Other; specify:	
Autopsy performed:	
□ No	

- Yes
- Unknown

BEST RESPONSE Complete only for the first annual follow-up Not applicable for Inborn Errors
Best clinical/biological response after HCT* (observed before any subsequent treatment):
Date best response first observed: / _ / _ (YYY/MM/DD) Unknown
* Indicate the best clinical/biological response after HCT corresponding to indication diagnosis by selecting from the list provided in Appendix 1

ЕВМТ	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Type HCT Treatment Date / _ / _ (YYYY/MM/DD)
	GRAFT FUNC	TION
the absens No Yes: D Unknov Complete fo	t function (defined as: frequent dependence on blood an se of other explanations, such as disease relapse, drugs, Pate of poor graft function: / / (YYYY/MM wn or every chimaerism test performed since last follow-u	or infection): /DD) Unknown
	n test date:// (YYYY/MM/DD)	iown
Source of c	cells tested: 🔲 Peripheral blood	
	Bone marrow	
Global: Myeloid T-cells (0 B-cells (0 CD34+ 0	type and complete relevant test results: % donor Unknown cells (i.e. CD33, CD15 or CD14):% donor U CD3):% donor Unknown CD19 or CD20):% donor Unknown cells:% donor Unknown ell type; specify cells;% donor	Inknown
copy and fill-	-in this table as many times as necessary.	
	PREVENTIVE TH (Complete only if the patient rece	
☐ No ☐ Yes; In ☐ ☐ Unknov ☐ Unknov ☐ No ☐ Yes; [☐	wn vir used as CMV prophylaxis during this follow-up per] Started in this follow-up period; Start date: / _] Ongoing since previous follow-up Letermovir treatment stop?] No	iod:
	wn	

EBMT	EBMT Centre Identification Code (CIC): Treatment Type HCT Hospital Unique Patient Number (UPN): Treatment Date /(YYYY/MM/DD) Patient Number in EBMT Registry: Treatment Date /(YYYY/MM/DD)
Extended datase	et
	Antimicrobial prophylaxis
this follow-up r If yes, what ty	pe of prophylaxis? Antibacterial Antifungal Antiviral Antiphylaxis
	Antibacterial
Antibiotic (select all that w	vere administered)
Ciprofloxaci	n: Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown
Levofloxacir	Started in this follow-up period; Start date://(YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown
Moxifloxacir	 Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Ongoing since previous follow-up Unkown
Penicillin:	 Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Ongoing since previous follow-up Unkown
	able antibiotic: Started in this follow-up period; Start date://(YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown ntibacterial prophylaxis was discontinued://(YYYY/MM/DD) Ongoing Unknown



Antimicrobial prophylaxis continued

Extended dataset	
	Antiviral
Did the patient receive CMV proph No (i.e. no prophylaxis or only let	ylaxis other than or in addition to letermovir during this follow-up period? ermovir)
Yes: Which drugs were used? (select all that apply)	 High-dose acyclovir High-dose valacyclovir
Note: letermovir is not included as this is requested on the core	 Gancyclovir intravenous Valgancyclovir
dataset. Do not consider letermovir for 'Other drug'.	 Foscarnet Other drug
, i i i i i i i i i i i i i i i i i i i	xis was discontinued: / / (YYYY/MM/DD) 🔲 Ongoing 🔲 Unknown
or valacyclovir during this follow-u	s for varicella-zoster virus (VZV) or herpes simplex virus (HSV) with either acyclovir up period? (Only for allo-HCT, not auto-HCT) rophylaxis was discontinued:// (YYYY/MM/DD) Ongoing Unknown
post-transplant lymphoproliferati auto-HCT	or another anti-CD20 monoclonal drug as prophylaxis for Epstein-Barr virus ve disorder (EBV-PTLD) during this follow-up period? (<i>Only for allo-HCT, not</i>
Yes	via far hanatitia R virus (UR)() during this follow up pariod?
	kis for hepatitis B virus (HBV) during this follow-up period?
Yes: Which drugs were used (select all that apply)	 Lamivudine Entecavir Tenofovir Other drug
Final date HBV prophyla	axis was discontinued: / _ / _ (YYYY/MM/DD) 🔲 Ongoing 🔲 Unknown



Antimicrobial prophylaxis

Extended dataset	
	Antifungal
Antifungal (select all that wer	re administered)
Fluconazole:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up
Voriconazole:	 Unknown Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up
Posaconazole:	 Unknown Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown
ltraconazole:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown
Caspofungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown
🔲 Micafungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown
🗌 Anidulafungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown
Ambisome: ☐ (IV or inhalations)	 Started in this follow-up period; Start date:// (YYYY/MM/DD) □ Unknown Ongoing since previous follow-up Unknown
Final date antifu	ngal prophylaxis was discontinued: / _ / _ (YYYY/MM/DD) 🛛 Ongoing 🔲 Unknown



Antimicrobial prophylaxis continued

		Antifungal
Did the patient receiv	e prophylaxis for <i>l</i>	Pneumocystis jirovecii pneumonia (PJP) during this follow-up period?
🔲 No		
	Yes: Which drugs were used? (select all that apply)	Trimethoprim-sulfamethoxazole
(select		
		Atovaquone
		Pentamidine inhaled
		Pentamidine intravenous
		Other drug
Final da	te prophylaxis was	s discontinued: / _ / (YYYY/MM/DD) 🔲 Ongoing 🔲 Unknown

ЕВМТ	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type 🔲 HCT
	Patient Number in EBMT Registry:	Treatment Date / _ / _ (YYYY/MM/DD)
Extended da	ataset	
	Pre-emptive	viral therapy
Did the patie this follow-u	ent receive pre-emptive therapy for a viral infecti up period?	ion during 🔲 No 🔄 Yes
-	, for what virus? CMV EBV t all that apply)	
	pre-emptive therapy for each CMV episode that	
	eatment start date:////YYY/MM/D	D) 🗌 Unknown
	al(s) used: all that apply)	
🔲 Valga	ancyclovir	
🔲 Ganc	cyclovir intravenous	
E Fosc	arnet	
Cidof	fovir	
🔲 Marik	pavir	
🔲 Spec	sific CMV T-cell	
🗌 Othe	r drug	
Was thi	is episode of CMV infection due to a resistant CM	/V strain?
🔲 No	Yes Unknown	
	often as necessary to reflect all episodes that occur	
	pre-emptive therapy for each EBV episode that	
	eatment start date: / _ / _ / _ (YYYY/MM/DI	D) 🔲 Unknown
	al(s) used: all that apply)	
	kimab	
	cific EBV T-cells	
	er drug	
Copy as	often as necessary to reflect all episodes that occur	red

EBN	EBMT Centre Identification Code (CIC):		Treatment Type 🔲 HCT
	Patient Number in EBMT Registry:		Treatment Date / _ / (YYYY/MM/DD)
	COMPLICATIO	DNS SINCE THE I	AST REPORT
		GvHD Allogeneic HCT onl	V
Did graf	t versus host disease (GvHD) occur during	-	
_	(proceed to 'Complications since the last repor		
 Yes:	Did the patient receive a systemic/immu	nosuppressive trea	tment for GvHD during this follow-up period?
	□ No		
	\Box Yes: \Box Started in this follow-up period;	Date treatment sta	r ted: / / (<i>YYYY/MM/DD</i>)
	Ongoing since previous follow-u	р	
	Treatment stopped: 🗌 No 🗋 Yes; Sto 🗍 Unknow		nt: //(<i>YYYY/MM/DD</i>) ☐ Unknown
	Unknown		
🗌 Unk	known (proceed to 'Complications since the las	t report - Non-infect	ious complications')
Did acu	te GvHD occur during this follow-up period	?	
🗌 No			
☐ Yes:	: 🔲 Started in this follow-up period; Date of c		(YYYY/MM/DD) 🔲 Unknown
	─ Ongoing since previous follow-up		—
	Maximum observed organ severity score	during this period:	
s		□ 2 □ 3	☐ 4 ☐ Not evaluated ☐ Unknown
		$\square 2 \qquad \square 3$	□ 4 □ Not evaluated □ Unknown
		$\square 2 \qquad \square 3$	☐ 4 ☐ Not evaluated ☐ Unknown
	Ipper GI tract: $\Box 0$ (none)		\square Not evaluated \square Unknown

		-					
Skin:	🔲 0 (none) 🗌 1	2	<u> </u>	4	□ Not evaluated	🔲 Unknowr
Liver:	🔲 0 (none) 🗌 1	2	<u> </u>	4	☐ Not evaluated	
Lower GI tract:	🔲 0 (none) 🗌 1	2	□ 3	□ 4	☐ Not evaluated	Unknow
Upper GI tract:		🗌 0 (none)	1	1	☐ Not evaluated	d 🔲 Unknown	
Other site affected:		🗌 No	י 🗆	Yes; specify: _			
Overall maximum	grade obser	rved: 🔲 1	2	□ ³ □	4 🔲 Unknowr	n 🗌 Not evalua	ted
Steroid-refractory	acute GvHD): 🗌 No					
		☐ Yes: ☐	Started i follow-up		Date of onse	t://	(YYYY/MM/DI
			Ongoing previous	since follow-up			
		Unknov	/n				
aGvHD resolved:	🗌 No						
	🗌 Yes; 🛛	Date of aGvH	D resolut	tion: / _	/_(YYYY/MN	//DD) 🔲 Unknow	n
	Unknov	vn					
Inknown							

_



Treatment Type	🗌 нст

COMPLICATIONS SINCE THE LAST REPORT

-- GvHD --

Allogeneic HCT only

	aGvHD first line	treatment	
id the patient receive sterc nis follow-up period? Steroid details during this	bids as first line treatment of aGvHD follow-up period:	during 🗌 Na	o 🗌 Yes 🔲 Unknown
Name of steroid	Treatment started / date (YYYY/MM/DD)	Initial dose (mg/kg/day)	Treatment stopped / date (YYYY/MM/DD)
 Prednisolone Methylprednisolone Other; specify: 	Started in this// follow-up period; Duknown Ongoing since previous follow-up	 Unknown	No Yes:// Unknown Unknown
 Prednisolone Methylprednisolone Other; specify: 	Started in this// follow-up period;// Ongoing since previous follow-up	 Unknown	No Yes:// Unknown Unknown
Vere other systemic drugs luring this follow-up perio yes, select the drugs belo select all that apply)	, ,	_	e EBMT Registry] No Yes Unknown
ame of drug/strategy ECP Ruxolitinib MMF Cyclosporin A Tacrolimus Sirolimus Other; specify:			



Extended dataset

aGvHD first line treatment continued							
Steroid refractory definition covers other subtypes, such as dependent and intolerant, but 'Steroid Refractory' (SR) will be used as an umbrella term in this form							
Refractory: progression in any organ within 3, 4 or 5 days of therapy onset with >= 2 mg/Kg/day of prednisone equivalent, or failure to improve within 5 to 7 days of treatment initiation, or incomplete response after more than 28 days of immunosuppressive treatment including steroids. Dependent: Inability to taper prednisone under 2 mg/Kg/day after an initially successful treatment of at least 7 days or as the recurrence of aGVHD activity during steroid tapering.							
How did aGvHD respond to steroids during this follow-up period? (according to the definitions above)							
Steroid sensitive: 🔲 No 🦳 Yes 🦳 Unknown							
If steroid sensitive, please continue at 'Complications since the last report"							
Steroid refractory: 🔄 No 🔄 Yes 🔄 Unknown							
Steroid dependent: No							
\square Yes: \square Started in this follow-up period: Date of onset: $____/__/__$ \square Unknown							
☐ Ongoing since previous follow-up							
Unknown							
Steroid refractory/dependent aGvHD							
Did the patient receive treatment for SR/SD aGvHD NO Yes: Started in this Unknown during this follow-up period?							
(after steroid refractoriness/dependence was established)							
if SR/SD aGvHD treatment started in this follow-up period:							
Overall aGvHD grade at start of SR/SD GvHD treatment: 0 1 2 3 4 Not evaluated Unknown							
Organ(s) involved at start of SR/SD GvHD treatment:							
Organ Stage (Glucksberg scale)							
Skin 🔄 Stage 0 🔄 Stage 1 📄 Stage 2 📄 Stage 3 📄 Stage 4 📄 Not evaluated 📄 Unknown							
Liver 🗌 Stage 0 🗌 Stage 1 📄 Stage 2 📄 Stage 3 📄 Stage 4 📄 Not evaluated 📄 Unknown							
Lower GI tract Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Not evaluated Unknown							
Upper GI tract Stage 0 Stage 1 Not evaluated Unknown							



Treatment Type	нст

Extended dataset

Steroid refractory/dependent aGvHD continued

Drugs given in this line of treatment during this follow-up period

Line	of	treatment
------	----	-----------

Name of drug/ strategy (select all that applies)	Started / date (YYYY/MM/DD))	Stopped / date (YYYY/MM/DD)
	Started in this follow-up period;/ [Ongoing since previous follow-up	Unknown	 No Yes: / / □ Unknown □ Unknown
🔲 Ruxolitinib	Started in this follow-up period;/ [Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown
	Started in this follow-up period;// [Ongoing since previous follow-up	Unknown	 □ No □ Yes:// □ Unknown □ Unknown
Cyclosporin A	Started in this follow-up period;/ [Ongoing since previous follow-up	_ Unknown	No Yes:// Unknown Unknown
Tacrolimus	Started in this follow-up period;// [Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown
☐ Sirolimus	 Started in this follow-up period;// Ongoing since previous follow-up 	🗌 Unknown	No Yes: / / Unknown Unknown
Other; specify:	 Started in this follow-up period; / / / Ongoing since previous follow-up 	Unknown	No Yes: / / Unknown Unknown

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



Treatment Type	🗌 нст
----------------	-------

Extended dataset

Steroid	refractory/dependent aGvHD
	continued

Organ involved during the course of treatment and response to the line of treatment during this follow-up period:

Organ involved during the course of treatment	Organ(s) involved during the course of treatment and Best response achieved	Date best response assessed (YYYY/MM/DD)
Skin	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Liver	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Lower GI tract	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Upper GI tract	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Overall (if organ specific is not available)	🗌 CR 🔲 PR 🔄 Progression 📄 Stable/no change 📄 Unknown	//

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



	COMPLICATIONS	SINCE	THE LAST	REPORT	continued
--	---------------	-------	----------	--------	-----------

_ _

-- GvHD --

Allogeneic HCT only

Did chronic GvHD occur during this follow-up period?

🗌 No							
Ves:	Started in this follo	w-up period; D	ate of ons	set: / /	(YYY)	(/MM/DD) 🔲 Unknown	
	Ongoing since pre	vious follow-up					
	Ongoing since previous follow-up Maximum NIH score during this period: Mild Moderate Severe Unknown Unknown Not evaluated Not evaluated						
	Maximum observed o	organ severity	score du	ring <u>this period</u> :	:		
]	Skin:	□ 0 (none)	□1	□ 2	□ 3	☐ Not evaluared	Unknown
	Oral:	0 (none)		2	3	□ Not evaluated	Unknown
	Gastrointestinal:	0 (none)	1	2	3	Not evaluated	Unknown
	Eyes:	🗌 0 (none)	1	<u>□</u> 2	<u> </u>	Not evaluated	Unknown
	Liver:	🗌 0 (none)	1	2	<u> </u>	Not evaluated	Unknown
	Joints and fascia:	🗌 0 (none)	1	2	3	Not evaluated	Unknown
	Lungs:	🗌 0 (none)	1	2	3	Not evaluated	Unknown
	Genitalia:	🗌 0 (none)	1	2	🗌 З	Not evaluated	🔲 Unknown
	Other site affected:	🗌 No	Yes; s	specify:			
Steroid-refractory chronic GvHD: No Yes: Started in this Date of onset:// Unknown follow-up period; (YYYY/MM/DD)							
	Ongoing since previous follow-up						
cGvHD resolved: 🔲 No							
─ Yes; Date of cGvHD resolution: / _ / _ (YYYY/MM/DD) □ Unknown							
	Was overlap syndrome observed:						
Unknown							

ЕВМТ	Hospital Uniqu	Identification Code (CIC): ue Patient Number (UPN): er in EBMT Registry:	Treatment Type HCT Treatment Date/ _/(YYYY/MM/DD)		
Extended data	set				
		cGvHD first line	treatment		
during this fo	llow-up perio	roids as first line treatment of cGvHD d? s follow-up period:	🗌 No 📋 Yes	Unknown	
	of steroid	Treatment started / date (YYYY/MM/DD)	Initial dose (mg/kg/day)	Treatment stopped / date (YYYY/MM/DD)	
Predniso	ednisolone	 Started in this follow-up period; Unknown Ongoing since previous follow-up 	Unknown	No Yes:// Unknown Unknown	
Predniso	ednisolone	 Started in this// follow-up period; Unknown Ongoing since previous follow-up 	Unknown	No Yes: / / Unknown Unknown	
	llow-up perio the drugs bel apply) /strategy	s/strategies used to treat cGvHD in the d: (other than steroids) ow:		No 🗌 Yes 🔲 Unknown	
☐ Cyclospon ☐ Tacrolimus ☐ Sirolimus ☐ Other; spe	3				
Refractory: prog of prednisone for Dependent: inab attempts, separat	ression of GvHD 1-2 months. ility to control GV ted by at least 8 w	while on prednisone at >= 1 mg/Kg/day for 1-2 wee HD symptoms while tapering prednisone below 0.2	eks or stable GvHD (25 mg/Kg/day (or 0.5		
Steroid se If steroid sen: Steroid re	sitive, please con fractory:	tinue at 'Complications since the last report"	Date of onset	t:// □ Unknown	
		Yes: Started in this follow-up period; Ongoing since previous follow-u Unknown		:// 🔲 Unknown)	

EBMT	Hospital Uniq	lue Patient Nur	Code (CIC): nber (UPN): _ egistry:			tment Type HCT		
							(' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	
Extended dat	aset							
		Ste	roid refracto	ory/depende	ent/intolera	nt cGvHD		
Did the pa follow-up	atient receive period?	treatment fo	r SR/SD/SI c0	GvHD during	this 🗌 No	Yes: Started		Iown
	oid refractorine	ss/dependen	ce/intolerance	was establis	hed)	Ongoing		
if SR/SD/SI	CGvHD treatm	ent started in	this follow-up	period:		— previous	s follow-up	
Overall cG	vHD grade at s	start of SR/S	D/SI GvHD tr	eatment: 🔲	Mild 🔲 Mode	erate 🔲 Severe 🗌 Not	evaluated 🔲 Unkr	nown
Organ(s)	involved at s	tart of SR/SD)/SI GvHD tre	atment:				
Skin:		0 (none)	1	2	3	□ Not evaluared	Unknown	
Oral:		🗌 0 (none)	1	2	3	Not evaluated	Unknown	
Gastroint	testinal:	0 (none)	1	2	3	Not evaluated	Unknown	
Eyes:		🗌 0 (none)	1	2	3	☐ Not evaluated	Unknown	
Liver:		🗌 0 (none)	1	2	3	☐ Not evaluated	Unknown	
Joints an	d fascia:	0 (none)	1	2	3	Not evaluated	Unknown	
Lungs:		0 (none)	1	2	3	☐ Not evaluated	Unknown	
Genitalia		0 (none)	1	2	3	☐ Not evaluated	Unknown	
Other site	e affected:	🗌 No	Yes; spe	cify:				



Treatment Type

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Extended dataset

Steroid refractory/dependent/intolerant cGvHD

Drugs given in this line of treatment during this follow-up period

Line of treatment ____

Name of drug/ strategy (select all that applies)	Started / date (YYYY/MM/DD)		Stopped / date (YYYY/MM/DD)
	Started in this follow-up period; / / /		□ No
	Ongoing since		□ Yes:// □ Unknown
	previous follow-up		Unknown
Ruxolitinib	Started in this follow-up period;		□ No
	Ongoing since		Yes:// Unknown
	previous follow-up		
MMF/CellCept	Started in this follow-up period;//	🔲 Unknown	□ No
	Ongoing since previous follow-up		☐ Yes:// ☐ Unknown
	Started in this		Unknown No
🔲 Belumosudil	follow-up period;//	Unknown	□ Yes:// □ Unknown
	Ongoing since previous follow-up		
	Started in this follow-up period;//	🔲 Unknown	No
🔲 Ibrutinib	Ongoing since		Yes:// Unknown
	previous follow-up Started in this		
Everolimus	└┘ follow-up period;//	Unknown	
	Ongoing since previous follow-up		Yes:// Unknown
Sirolimus	Started in this follow-up period; / / /	🔲 Unknown	
	Ongoing since previous follow-up		□ ^{Yes:} // □ Unknown
	Started in this		
Cyclosporin A	└─ follow-up period; / / /	Unknown	□ Yes:// □ Unknown
	Ongoing since previous follow-up		
	Started in this follow-up period; / _ / / / / / / / / _ / / _ / _ / / _ / / _ / / _ / / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / / _ / _ / / _ / _ / / _ / _ / / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / / _ / / / _ / / / / _ /	🔲 Unknown	□ No
Tacrolimus	Ongoing since		□ Yes:// □ Unknown
	previous follow-up		Unknown
Other; specify:	Started in this follow-up period; $ / - / - /$	🗌 Unknown	No
	Ongoing since	_	Yes:// Unknown Unknown
	└── previous follow-up		

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



Steroid refractory/dependent/intolerant cGvHD

Extended dataset

Organ involved during the course of treatment and response to the line of treatment during this follow-up period:

Organ involved during the course of treatment	Organ(s) involved during the course of treatment and Best response achieved	Date best response assessed (YYYY/MM/DD)
Skin	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Oral	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Gastrointestinal	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Eyes	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Liver	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Joints and fascia	No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown	// Unknown
Lungs	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Genitalia	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Overall (if organ specific is not available)	🗌 CR 🔄 PR 🔄 Progression 🗌 Stable/no change 🗌 Unknown	// Unknown

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry

(EBMT	

	COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications				
	Did non-infectious complications occur during the follow-up period? (Please only report toxic events here that are above Grade 2 and not linked to GvHD and/or infections) No (proceed to 'Complications since the last report - Infectious complications') Yes (report in the table below)				
Se	condary graft failure				
	mplication observed during this follow-up period? No				
	Yes: Newly developed Ongoing since previous assessment Unknown				
Ma	aximum grade observed during <u>this period</u> : 🔲 Non-fatal 🛛 📋 Fatal				
0	nset date (YYYY/MM/DD): / / Unknown Only if newly developed				
R	esolved: No				
	☐ Yes; Stop date (<i>YYYY/MM/DD):</i> / _ ☐ Unknown ☐ Unknown				
Ca	rdiac event				
	Complication observed during this follow-up period? Ves: No* Ves: Newly developed Ongoing since previous assessment Unknown				
Ma	aximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown				
	Onset date (YYYY/MM/DD): / Unknown Only if newly developed Resolved: _ No Yes; Stop date (YYYY/MM/DD): / _ / Unknown				
	ntral nervous system (CNS) toxicity				
CO	mplication observed during this follow-up period? I No* Yes: Newly developed Ongoing since previous assessment Unknown				
Ma	aximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown				
	set date (YYYY/MM/DD):// Unknown Only if newly developed solved:No				
	Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown Unknown				
Ga	Gastrointestinal (GI) Toxicity (non-GvHD and non-infectious related)				
Со	Complication observed during this follow-up period?				
	🔲 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessmen 🗌 Unknown				
Ма	ximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown				
	Onset date (YYYY/MM/DD):/ Unknown Only if newly developed Resolved: No				
	☐ Yes; Stop date (<i>YYYY/MM/DD):</i> / ☐ Unknown ☐ Unknown				

(EBMT	
	/	

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ _ / _ _ (YYYY/MM/DD)

COMPLICATIONS	SINCE T	HE LAST	REPORT
NI			

-- Non-infectious complications --

.iver disorder
Complication observed during this follow-up period? 🔲 No*
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessme
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown
Dnset date (YYYY/MM/DD): / / Unknown Only if newly developed
Resolved: 🔲 No
☐ Yes; Stop date (<i>YYY/MM/DD</i>): / / Unknown
Renal failure (chronic kidney disease, acute kidney injury)
Complication observed during this follow-up period? 🔲 No*
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessme 🗍 Unknown
<i></i>
Dnset date (YYYY/MM/DD): / _ / _ D Unknown Only if newly developed
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown
Respiratory disorders
Complication observed during this follow-up period? 🔲 No*
🗌 Yes: 📋 Newly developed 🔲 Ongoing since previous assessme
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown
Dnset date (YYYY/MM/DD): / _ / Unknown Only if newly developed
Resolved: 🗌 No
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown
Skin Toxicity (non-GvHD and non-infectious related)
Complication observed during this follow-up period? 🔲 No*
🗌 Yes: 📋 Newly developed 🔲 Ongoing since previous assessme
Aaximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown
Dnset date (YYYY/MM/DD): / _ / Unknown Only if newly developed
Resolved: 🗌 No
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown

* Grade 0-2

(EBMT	
	-	

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications		
Vascular event		
Complication observed during this follow-up period?	 No* Yes: Newly developed Ongoing since previous assessment Unknown 	
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown	
Onset date (YYYY/MM/DD):// Un Resolved: □ No	known Only if newly developed	
Yes; Stop date (YYYY/MM/DD):	_/ / Unknown	
Unknown		
Avascular necrosis (AVN)		
Complication observed during this follow-up period?	□ No*	
	 Yes: Newly developed Ongoing since previous assessment Unknown 	
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown	
Onset date (<i>YYYY/MM/DD</i>): / / Un Resolved: □ No	known Only if newly developed	
<pre>Yes; Stop date (YYYY/MM/DD):</pre>	_// Unknown	
Cerebral haemorrhage		
Complication observed during this follow-up period?	□ No*	
	 Yes: Newly developed Ongoing since previous assessment Unknown 	
Maximum CTCAE grade observed during this period	3 4 5 (fatal) Unknown	
Onset date (YYYY/MM/DD): / / Un Resolved: □ No	known Only if newly developed	
Yes; Stop date (YYYY/MM/DD):	_// 🔲 Unknown	
Haemorrhage (other than cerebral haemorrhage)		
Complication observed during this follow-up period?		
	☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment ☐ Unknown	
Maximum CTCAE grade observed during this period:		
Onset date (YYYY/MM/DD):// Un	known Only if newly developed	
Resolved: No		
 Yes; Stop date (YYYY/MM/DD): Unknown 	_// Unknown	

(EBN	ΛL

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ _ / _ _ (YYYY/MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications			
Cerebral thrombosis			
Complication observed during this follow-up period?			
🔲 Yes: 🔲 Newly developed 🗍 Ongoing since previous assessmen			
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD):/ Unknown Only if newly developed Resolved: No			
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown			
Cytokine release syndrome (CRS)			
Complication observed during this follow-up period? 🔲 No*			
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessmen			
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD):/ Unknown Only if newly developed Resolved: No			
Yes; Stop date (YYYY/MM/DD):/ Unknown			
Haemophagocytic lymphohistiocytosis (HLH)			
Complication observed during this follow-up period?			
🗌 Yes: 🔲 Newly developed 🗌 Ongoing since previous assessmen			
Maximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD):/ Unknown Only if newly developed Resolved: No			
Yes; Stop date (YYYY/MM/DD): / Unknown			
Pure red cell aplasia (PRCA)			
Complication observed during this follow-up period? 🔲 No			
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessmen			
Maximum grade observed during this period: 🔲 Non-fatal 🛛 📋 Fatal			
Onset date (YYYY/MM/DD): / _ / _ Unknown Only if newly developed			
Resolved: No			
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown			

* Grade 0-2

EBMT Ho	ospital Unique Patient Number (UPN):	atment Type HCT		
	COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications			
Destaviav versible	encentral another considering (DDEC)			
	encephalopathy syndrome (PRES)			
Complication obser	ved during this follow-up period?	eloped 🔲 Ongoing since previous assessment		
Maximum grade obs	served during <u>this period</u> : 🗌 Non-severe 🗌 Severe 🛛	🗌 Fatal 🛛 🔲 Unknown		
	IM/DD): / _ / Unknown Only if newly d			
Yes;	Stop date (YYYY/MM/DD):// Unknov	vn		
Unkn	own			
Transplant-associat	ed microangiopathy (TMA)			
Complication obser	rved during this follow-up period? 🔲 No*			
		eloped Ongoing since previous assessment		
Maximum avada ak				
Maximum grade ob	served during this period: Non-severe Severe	Unknown		
Onset date (YYYY/// Resolved: No	/IM/DD): / _ / Unknown Only if newly de	eveloped		
☐ Yes;	Stop date (YYYY/MM/DD):/ Unknow	/n		
🗌 Unkn	lown			
Extended dataset				
Was TA-TMA tre	atment given during this follow-up period: 🛛 🗌 No	🗌 Yes 📄 Unknown		
TA-TMA treatme	nt given during this follow-up period			
Line of tre	atment			
Name of drug	Start date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)		
Defibrotide	Started in this follow-up period; $____'_='=='$ Unknown	□ No □ Yes:// Unknown		
	Ongoing since previous follow-up			
Eculizumab	Started in this follow-up period; $__\/\/\$ Unknown	□ No □ Yes:// □ Unknown		
	Ongoing since previous follow-up			
Narsoplimab	Started in this follow-up period; $$ Unknown	□ No □ Yes: / / □ Unknown		
	Ongoing since previous follow-up			



COMPLICATIONS SINCE THE LAST REPORT

-- Non-infectious complications --

Extended dataset

Name of drug	Start date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)	
	Started in this follow-up period; $//$ Unknown		
Pegcetacoplan	Ongoing since previous follow-up	Yes:// Unknown Unknown	
🔲 Iptacopan	Started in this follow-up period;// Unknown Ongoing since	□ No □ Yes:// □ Unknown	
	└┘ previous follow-up		
🗖 Danicopan	Started in this follow-up period; $^{\prime}^{\prime}$ Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Ravulizumab	Started in this follow-up period;/ / Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Other; specify:	Started in this follow-up period; $____/__/__/__$ Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Other TA-TMA treatment given in this line of treatment during this follow-up period:			
Renal replacement therapy performed: No Yes: Started in this			

	Started in this Yes: Started in this follow-up period;/ Unknown Ongoing since previous follow-up
Mechanical ventilation performed:	Unknown No Started in this
	$\Box \text{ Yes:} \Box \text{ follow-up period; } ___/_/\ \Box \text{ Unknown}$
	Ongoing since
	☐ previous follow-up ☐ Unknown
Exchange plasmapheresis performed:	 No Yes: ☐ follow-up period;// ☐ Unknown Ongoing since previous follow-up
Response to this line of TA-TMA treatment dur	ing this follow-up period
Did the patient achieve complete response?] No 🔄 Yes 📋 Unknown
Defined as normal LDH, no organ manifestations,	high-risk TA-TMA harmonisation criteria not fulfilled anymore
If yes, date of complete response: $___$	II_ Unknown
If no, did the patient achieve partial respo	nse? 🗌 No 🔄 Yes 🔄 Unknown
Defined as LDH decreased, residual organ r	nanifestations, high-risk TA-TMA harmonisation criteria not fulfilled anymore
If yes, date of partial response:	/_/ Unknown

Copy and print this table as many times as needed, or enter the data directly into the EBMT Registry



Treatment Date _ _ _ / _ / _ (YYY//MM/DD)

		TIONS SINCE THE LAST REP on-infectious complications	ORT
eno-occlusive disease (VOD)			
aximum grade observed during	ng <u>this period</u> :	☐ Yes: ☐ Newly develop ☐ Unknown	bed Dongoing since previous assessment Very severe D Fatal D Unknowr loped
☐ Yes; Stop date ☐ Unknown	(YYYY/MM/DD): _	// Unknown	
Extended dataset VOD treatment given during VOD treatment given during			Unknown
Line of treatment	1		
Name of drug		date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)
Defibrotide	Started in this follow-up perio Ongoing since previous follow	d; / / 🔲 Unknown /-up	 No Yes: / / □ Unknown □ Unknown
Other; specify:	Started in this follow-up period Ongoing since previous follow		 □ No □ Yes:// □ Unknown □ Unknown
Other VOD treatment give Renal replacement therap	i	eatment during this follow-up per	;/ Unknown
Mechanical ventilation pe	rformed:	No Started in this Yes: ☐ follow-up period; ☐ Ongoing since ☐ previous follow-u ☐ Unknown	;// Unknown
Extracoporeal membrane performed:	oxygenation	No Yes: Started in this follow-up period; Ongoing since previous follow-u	// Unknown
Defined as serum bilirubin <2 replacement therapy If yes, date of complete	plete response? mg/dL, no oxygen e response:	g this follow-up period No Yes Unknown support, eGFR >50% from baseline III Unknown ponse? No Yes Unkr	
If yes, date of par	tial response:	• • • •	or eGFR ≤50% from baseline before VOD



COMPLICATIONS SINCE THE LAST REPORT
Non-infectious complications

Dther complication observed during this follow-up period? No* Yes: Newly developed Ongoing since previous assessment Unknown
Specify: Consult appendix 4 for a list of complications that should not be reported (Indicate CTCAE term)
Maximum CTCAE grade observed 3 4 5 (fatal) Unknown
Onset date (YYYY/MM/DD):// Unknown Only if newly developed
Resolved: 🔲 No
Yes; Stop date (YYYY/MM/DD):/ Unknown

If more other complications occurred, copy and fill-in this table as many times as necessary.

* Grade 0-2



EBMT Centre Identification Code (CIC):	Treatment Type	🗌 нст	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date	//	(YYYY/MM/DD)

Extended dataset

Additional late complications

Indicate if any of the	following complications occurred during follow-up period:
Cataract diagnosis:	□ No
	Yes; Date first reported:// Unknown
	Did the patient undergo cataract surgery? 🗌 No 🔄 Yes 📋 Unknown
	Date of cataract operation: / / / Unknown
Thyroid disorder	□ No
requiring treatment:	Yes; Type of thyroid disorder: Hyperthyroidism
	Hypothyroidism
	Goiter
	Other; specify:
	Start date of treatment: / _ / _ Unknown
Osteoporosis	□ No
requiring treatment:	Yes; Start date of treatment: / _ / Unknown
Bone fracture:	□ No
	Yes; Bone involved:
	Date of fracture: / _ / Unknown
Iron overload	 No
requiring treatment:	Yes; Start date of treatment: / _ / Unknown
Dyslipidemia	
requiring treatment:	Yes; Start date of treatment:/ Unknown Unknown
Arterial hypertension	
requiring treatment:	Yes; Start date of treatment:// Unknown
Morbid obesity	
requiring treatment:	Yes; Start date of treatment:I Unknown Unknown
Mental health disorder	
requiring treatment:	☐ Yes; Diagnosis:
	Start date of treatment:/// Unknown
Cognitive function dis	order No
requiring treatment:	☐ Yes; Diagnosis:
	Start date of treatment:/ Unknown
	Unknown
Return to work/school	: No
	Yes; Involvement: Parttime
	Fulltime
	Unknown
	Date of return to work/school:/ Unknown



COMPLICATIONS SINCE THE LAST REPORT
Infectious complications

Do not report infections that were already reported as resolved on the previous assessment and did not reoccur. Did infectious complications occur during the follow-up period? No Consult appendix 4 for a list of complications that should not be reported
Yes (report all infection-related complications below)
Bacterial infection: No Yes
1) New or ongoing: Newly developed Ongoing since previous assessment Start date: / _ / _ (YYY/MM/DD) only if newly developed Unknown Gram-positive Gram-negative Other Pathogen*:
Infection with clinical implications: No
Yes: (select all that apply during this period) ☐ Symptoms/signs of disease
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: 🔲 No
☐ Yes; specify***:
Unknown
Resolved: 🗌 No 📄 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🔲 No 🛛 🗌 Yes 🔄 Unknown
2) New or ongoing: Newly developed Ongoing since previous assessment
Start date: / _ / _ / _ (YYY//M//DD) only if newly developed Unknown
Gram-positive Gram-negative Other
Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period)
Symptoms/signs of disease
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: 🗌 No
☐ Yes; specify***:
Unknown
Resolved: No Yes Unknown
(if patient died) Contributory cause of death: 🔲 No 🛛 🗌 Yes 📄 Unknown
If more than 2 bacterial infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2 ** Indicate CTCAE term by choosing from the list provided in Appendix 3 *** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5

(EBMT	

Treatment Date _ _ _ / _ / _ (YYY/MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Infectious complications continued
Viral infection: No Yes
1) New or ongoing: 🔲 Newly developed 🗌 Ongoing since previous assessment
Start date: / / (YYY/MM/DD) only if newly developed 🔲 Unknown
Pathogen*:
If the pathogen was CMV/EBV: Was this infection a reactivation? No
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs of disease
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period:
Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: 🗌 No 🔄 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🔲 No 📄 Yes 📄 Unknown
2) New or ongoing: 🔲 Newly developed 🗍 Ongoing since previous assessment
Start date: / _ / _ (YYY/MM/DD) only if newly developed Unknown
Pathogen*:
If the pathogen was CMV/EBV: Was this infection a reactivation? 🔲 No
Yes
Infection with clinical implications: \Box No \Box Yes: (select all that apply during this period)
□ Symptoms/signs of disease
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: 🗌 No 🔄 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🗌 No 📄 Yes 📄 Unknown
If more than 2 viral infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2 ** Indicate CTCAE term by choosing from the list provided in Appendix 3

*** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5



Treatment Type	🗌 нст

COMPLICATIONS SINCE THE LAST REPORT

-- Infectious complications -- continued

Fungal infection: 🗌 No 📄 Yes
 New or ongoing: Newly developed Ongoing since previous assessment Start date:// (YYYY/MM/DD) only if newly developed Unknown Yeasts Moulds Pathogen*:
Infection with clinical implications: \Box No \Box Yes: (select all that apply during this period)
Symptoms/signs of disease
Administration of pathogen-directed therapy Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: No Yes; specify***: Unknown
Resolved: 🔲 No 🛛 🗋 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🔲 No 📄 Yes 📄 Unknown
2) New or ongoing: Newly developed Ongoing since previous assessment
Start date:// (YYYY/MM/DD) only if newly developed Unknown Yeasts Moulds Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease
Administration of pathogen-directed therapy
Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: Intravascular catheter-related
Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown
If more than 2 fungal infections, copy and fill-in this table as many times as necessary.
* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2 ** Indicate CTCAE term by choosing from the list provided in Appendix 3

*** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5



Parasitic infection: No Yes 1) New or ongoing: Newly developed Ongoing since previous assessment
1) New or ongoing: 🔄 Newly developed 🔄 Ongoing since previous assessment
Start date: / _ / _ (YYY/MM/DD) only if newly developed D Unknown Protozoa D Helminths Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease
Administration of pathogen-directed therapy Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown 2) New or opgoing: Newly developed Opgoing since previous assessment
 2) New or ongoing: Newly developed Ongoing since previous assessment Start date:// (YYYY/MM/DD) only if newly developed Unknown Protozoa Helminths Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period)
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown
If more than 2 parasitic infections, copy and fill-in this table as many times as necessary. Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2

*** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5



COMPLICATIONS SINCE THE LAST REPORT
Infectious complications continued

Infection with unknown pathogen: No Yes: (for clinical infections without microbiological documentation, like pneumonia, cellulitis, etc.)				
1) New or ongoing: 🔲 Newly developed 🔲 Ongoing since previous assessment				
Start date:/ _/ _ (YYYY/MM/DD) only if newly developed Unknown				
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease				
Administration of pathogen-directed therapy				
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*:				
Localisation 2 (CTCAE term)*:				
Localisation 3 (CTCAE term)*:				
Intravascular catheter-related infection: 🖳 No				
Yes; specify**:				
Resolved: No Yes Unknown				
(if patient died) Contributory cause of death: 🔲 No 🛛 🗌 Yes 🔲 Unknown				
 2) New or ongoing: Newly developed Ongoing since previous assessment Start date:/ _ / _ (YYYY/MM/DD) only if newly developed Ongoing the special unknown Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease Administration of pathogen-directed therapy Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*:				
Localisation 2 (CTCAE term)*:				
Localisation 3 (CTCAE term)*:				
Intravascular catheter-related infection: 🔄 No				
☐ Yes; specify**:				
Unknown				
Resolved: No Yes Unknown				
(if patient died) Contributory cause of death: 🔲 No 👘 Yes 🦳 Unknown				
If more than 2 infections with unknown pathogen, copy and fill-in this table as many times as necessary.				

* Indicate CTCAE term by choosing from the list provided in Appendix 3

** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5

EBMT	EBMT Centre Identification Code (CIC Hospital Unique Patient Number (UPN	
	Patient Number in EBMT Registry:	
Extended data	aset	
	SARS	S-CoV-2 RELATED QUESTION
Did the pati	ent receive a vaccination against	SARS-CoV-2 during this follow-up period?
	Number of decase	
Yes:	Number of doses:	
🔲 Unknow		_/ _ / _ (YYYY/MM/DD) 🔲 Unknown
	SECONDARY MALIC	GNANCIES AND AUTOIMMUNE DISORDERS
	ary malignancy or autoimmune di	sorder occur since the last follow-up?
	s this disease an indication for a s	
	No (complete the non-indication diag	-
	Yes (complete the relevant indication	
	1	
	Ą	DDITIONAL TREATMENTS
Did the pat	tient receive any additional diseas	e treatment since the last follow-up?
🗌 No		
□ Yes; □		complete the "Treatment — non-HCT/CT/GT/IST" form
	Started in this follow-up period; Ongoing since previous follow-up	
L		
🗌 Unknowi	n	



ADDITIONAL CELL INFUSIONS

Did the	patient receive additional cell infusions (excluding a new HCT and CT) since the last follow-up?
Yes:	Is this cell infusion an allogeneic boost*? 🔲 No 👘 Yes
	* An allogeneic boost is an infusion of cells from the same donor without conditioning, with no evidence of graft rejection.
	Date of the allogeneic boost: / / (YYYY/MM/DD)
	Is this cell infusion an autologous boost? 🔲 No 📄 Yes
	Date of the autologous boost: / _ / (YYYY/MM/DD)
	nfusion is not a boost, attach the Cell Infusion (CI) sheet available in Appendix 6, completing as many appisodes of cell infusion that took place during this interval; then continue below.
Did the pa	tient receive subsequent HCT/CT (either at your or another centre)?

□ No □ Yes

If the patient had a subsequent HCT/CT, please, make sure that this subsequent treatment is registered using the appropriate treatment form before proceeding.



RELAPSE, PROGRESSION, RECURRENCE OF DISEASE OR SIGNIFICANT WORSENING (not relevant for Inborn errors)

55. for every relapse, progression, recurrence, significant worsening complete the questions below 7YPE: Relapse / Recurrence of disease	disease since last follow				g of organ function related to the		
□ (Continuous) progression / Significant worsening □ ate of relapse/progression/recurrence/worsening: / / (YYYY/MM/DD) □ Unknown Extended dataset In case of relapse or progression (CML only) Type of relapse: [select worst detected at this time point] Haematological; Disease status at relapse: □ Chronic phase □ Cytogenetic □ Unknown In case of relapse or progression (MPN only) Type of relapse: □ Unknown In case of relapse or progression: □ Haematological (select worst detected at this time point) □ Haematological (select worst detected at this time point) □ Unknown Malignant disorders only: Type of relapse/progression: Meduilary: No □ Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes □ No Yes Not evaluated □ CNS: No Yes □ Not evaluated Testes/Ovaries:	; for every relapse, prog	gression, re	currence, sig	nificant worsening comple	te the questions below		
Date of relapse/progression/recurrence/worsening:// (YYYY/MM/DD) Unknown Extended dataset In case of relapse or progression (CML only) Type of relapse:	Type: 🔲 Relapse / R	ecurrence	of disease				
Extended dataset In case of relapse or progression (CML only) Type of relapse: (select worst detected at this time point) Haematological; Disease status at relapse: Chronic phase Blast crisis Cytogenetic Unknown Molecular Unknown In case of relapse or progression (MPN only) Type of relapse: (select worst detected at this time point) Haematological (select worst detected at this time point) Molecular Unknown Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No No Yes Not evaluated CNS: No No Yes Not evaluated CNS: No No Yes Not evaluated CNS: No	Continuous	s) progressi	on / Significa	nt worsening			
In case of relapse or progression (CML only) Type of relapse: Chronic phase (select worst detected at this time point) Haematological; Disease status at relapse: Chronic phase Blast crisis Cytogenetic Unknown Molecular Unknown In case of relapse or progression (MPN only) Type of relapse: Haematological (select worst detected at this time point) Nolecular Unknown Unknown Kalignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: Skin: No Yes No Yes Not evaluated CNS: No Yes No Yes Not evaluated CNS: No Yes Not evaluated CNS: No <td>Date of relapse/progr</td> <td>ression/rec</td> <td>urrence/wor</td> <td>rsening: / / /</td> <td>(YYYY/MM/DD) 🔲 Unknown</td>	Date of relapse/progr	ression/rec	urrence/wor	rsening: / / /	(YYYY/MM/DD) 🔲 Unknown		
Type of relapse: Accelerated phase (select worst detected at this time point) Haematological; Disease status at relapse: Accelerated phase Blast crisis Cytogenetic Unknown Molecular Unknown In case of relapse or progression (MPN only) Type of relapse: Haematological (select worst detected at this time point) Haematological (select worst detected at this time point) Molecular Unknown Molecular Unknown Molecular Unknown Molecular In case of relapse or progression: Molecular Whether the point) Haematological (select worst detected at this time point) Molecular Unknown Molecular Whether the point) Molecular Involvement at time or relapse/progression: Molecular Involvement at time of relapse/progression: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No Yes Not evaluated Other: No Yes Not evaluated	Extended dataset	Extended dataset					
(select worst detected at this time point) International product status at returblet. Chromo product Accelerated phase Blast crisis Cytogenetic Unknown In case of relapse or progression (MPN only) Type of relapse: Haematological (select worst detected at this time point) Haematological (select worst detected at this time point) Molecular Unknown Unknown Malignant disorders only: Unknown Type of relapse/progression: Medullary: Medullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No No Yes Not evaluated	In case of relapse or p	orogression	(CML only)				
□ Cytogenetic □ Unknown □ Molecular □ Unknown In Case of relapse or progression (MPN only) Type of relapse: □ Haematological (select worst detected at this time point) □ Haematological □ Malignant disorders only: □ Unknown □ Malignant disorders only: □ Yes □ Type of relapse/progression: Molecular □ Unknown Matignant disorders only: □ Yes □ Unknown Extramedullary: No □ Yes □ Unknown Involvement at time of relapse/progression: Skin: □ No Yes □ Unknown Skin: □ No Yes □ Onterwork Involvement at time of relapse/progression: Skin: □ No □ Yes □ No Involvement at time of relapse/progression: Skin: □ No □ Yes □ Not evaluated □ □ Not evaluated □ □ Yes □ Not evalu	Type of relapse: (select worst detected at	this time poi	nt) 🗌 Haem	atological; Disease statu	Accelerated phase		
□ Molecular □ Unknown In case of relapse or progression (MPN only) Type of relapse: □ (select worst detected at this time point) □ □ Unknown Malignant disorders only: □ Type of relapse/progression: Molecular □ Unknown Malignant disorders only: Yes □ Unknown Extramedullary: No ○ Yes □ Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Skin: No ○ Yes ○ Yes <td></td> <td></td> <td></td> <td>onotio</td> <td></td>				onotio			
□ Unknown In case of relapse or progression (MPN only) Type of relapse: (select worst detected at this time point) □ Haematological □ Molecular □ Unknown Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Skin: No No Yes No Yes No Yes No Yes Involvement at time of relapse/progression: Skin: No No Yes No Y			_				
In case of relapse or progression (MPN only) Type of relapse: (select worst detected at this time point) Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No Yes Unknown If the relapse/progression: Involvement at time of relapse/progression: Skin: No Yes No tevaluated Testes/Ovaries: No Yes No tevaluated Testes/Ovaries: No Yes No tevaluated			Molec	ular			
Type of relapse: Haematological (select worst detected at this time point) Molecular Unknown Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No No Yes No Yes No Yes No Yes No Yes Involvement at time of relapse/progression: Skin: No Yes Not evaluated Testes/Ovaries: No No Yes Not evaluated Other: No			🔲 Unkno	own			
(select worst detected at this time point) Molecular Unknown Malignant disorders only: Unknown Medullary: No Yes Unknown Extramedullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: No Yes Not evaluated	In case of relapse or p	In case of relapse or progression (MPN only)					
Molecular Unknown Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No Yes Unknown Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No No Yes Not evaluated Testes/Ovaries: No No Yes No Yes Not evaluated Testes/Ovaries: No No Yes Not evaluated Other: Yes							
Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No No Yes Not evaluated Other: No	(select worst detected a	t this time po		ecular			
Malignant disorders only: Type of relapse/progression: Medullary: No Yes Unknown Extramedullary: No If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No No Yes No Yes No Yes No Yes No Yes No Yes Other: No			— — Unk	nown			
Medullary: No Yes Unknown Extramedullary: No Yes Unknown If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: No Yes Not evaluated	_	-					
If the relapse/progression was extramedullary or both medullary and extramedullary: Involvement at time of relapse/progression: Skin: NO Yes Not evaluated CNS: NO Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other:		÷		Unknown			
Involvement at time of relapse/progression: Skin: No Yes Not evaluated CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: No Yes Not evaluated	Extramedullary	: 🗌 No	🗌 Yes	Unknown			
Skin: No Yes Not evaluated CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: No Yes Not evaluated	If the relapse/prog	If the relapse/progression was extramedullary or both medullary and extramedullary:					
CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: Other: Yes Not evaluated	Involvement at tir	Involvement at time of relapse/progression:					
CNS: No Yes Not evaluated Testes/Ovaries: No Yes Not evaluated Other: Other: Yes Not evaluated	Skin:	□ No	🗌 Yes	☐ Not evaluated			
Testes/Ovaries: No Yes Not evaluated Other: Other Yes Yes			☐ Yes				
Other:	Testes/Ovaries	:					
	Other:		_				

copy and fill-in this table as many times as necessary.



Treatment Type	🗌 нст
----------------	-------

DISEASE STATUS

Disease specific

Disease status at this follow-up or at time of death*:

* Indicate the disease status at this follow-up or at time of death corresponding to indication diagnosis by selecting from the list provided in Appendix 1

PREGNANCY AFTER HCT

Has patient become pregnant or impregnated another person since last follow-up?

No; Extended dataset Was there an attempted pregnancy since last follow-up? No Yes Unknown				
Yes: Did the pregnancy result in a live birth?				
No; Date of spontaneous or induced termination:/ (YYYY/MM/DD) Unknown				
Yes; Year of birth: (YYYY) Month of birth: (MM) 🔲 Unknown				
Still pregnant at time of follow-up				
Unknown				
Extended dataset Conception method: Natural Assisted Unknown 				



Appendix 1

Best Response and Disease Status (Disease Specific)

Complete only one section with the main indication diagnosis for which HCT was given.

ACUTE LEUKAEMIAS	Go to page 37
CHRONIC LEUKAEMIAS	Go to page 37
PLASMA CELL NEOPLASMS (PCN)	Go to page 38
MPN, MDS, MDS / MPN OVERLAP SYNDROMES	Go to page 40
AUTOIMMUNE DISORDERS	Go to page 41
HAEMOGLOBINOPATHIES	Go to page 41
LYMPHOMAS	Go to page 42
SOLID TUMOURS	Go to page 42
BONE MARROW FAILURE SYNDROMES (BMF) including APLASTIC ANAEMIA (AA)	Go to page 42
OTHER DIAGNOSIS	Go to page 43
Inborn Errors	Go to page 44



Appendix 1

Best Response and Disease Status (Disease Specific)

Acute leukaemias (AML, PLN, Other)

	· · ·			
Complete remission	ı (CR)			
Not in complete rem	nission			
☐ Not evaluated				
Unknown				
Proceed to next page fo	or Diseases Status section			
Chronic leukaemias (CN	vIL, CLL, PLL, Other)			
Chronic Myeloid Leuka	<u>aemia (CML):</u>			
Chronic phase (CP);	; Number : 1 st 2 nd	☐ 3 rd or	higher 🗌	Unknown
	Haematological remission:	: 🗌 No	🗌 Yes	🔲 Not evaluated 📋 Unknown
	Cytogenetic remission:	🗌 No	🗌 Yes	🗌 Not evaluated 📋 Unknown
Extended dataset				
In case of NO cytogene Cytogenetic details :	<mark>etic remission</mark> t(9;22) positive metaphases:		(%)	🔲 Not evaluated 🔲 Unknown
	t(9;22) positive cells detected	d by FISH:		(%) 🔲 Not evaluated 📋 Unknown
	Molecular remission:	🗌 No	🗌 Yes	🗌 Not evaluated 📋 Unknown
Extended dataset In case of NO molecular remission BCR::ABL1 variant allele frequency (VAF):% Unknown				
Accelerated phase;	Number: 1 st 2 nd	3rd or	higher 🔲	Unknown
Extended dataset				
Cytogenetic details: t	(9;22) positive metaphases:		_ (%)	🗌 Not evaluated 📋 Unknown
ti	(9;22) positive cells detected b	by FISH: _		_ (%) 🔲 Not evaluated 🔲 Unknown
DCD: ADI 1 verient el			Jnknown	
BCR::ABLI Variant ai	llele frequency (VAF):	_% (
Blast crisis; Number	": □ 1 st □ 2 nd □	3 rd or high	ner 🗌 Un	iknown
Extended dataset				
	(9;22) positive metaphases:			🔲 Not evaluated 🔲 Unknown
t	(9;22) positive cells detected b			_ (%) 🔲 Not evaluated 🔲 Unknown
BCR::ABL1 variant al	lele frequency (VAF):	_% 🔲 L	Jnknown	
☐ Not evaluated				
Unknown				

Proceed to next page for Diseases Status section



Appendix 1

Best Response and Disease Status (Disease Specific)

Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) and other chronic leukaemias:

Complete remission (CR)		
Partial remission (PR)		
Progression: Resistant to last regimen	Sensitive to last regimen	Unknown
Stable disease (no change, no response/loss of re	esponse)	
Relapse		
□ Not evaluated		
Unknown		

Proceed to next page for Diseases Status section

Plasma cell neoplasms (PCN)

Complete remission (CR)	Number: 🔲 1st			
Stringent complete remission (sCR)				
Very good partial remission (VGPR)	 ☐ 3rd or higher			
Partial remission (PR)	Unknown			
Relapse	_			
Progression				
Stable disease (no change, no response/loss of response)				
Not evaluated				
Unknown				

Extended dataset

Immunoglobulin-related (AL) Amyloidosis only

Organ response during this follow-up period:

Heart	□ Response □ No change □ Progression □ Not involved □ Not evaluated	Unknown
Kidney	Response No change Progression Not involved Not evaluated	Unknown
Liver	Response No change Progression Not involved Not evaluated	Unknown
Peripheral nervous system	☐ Response ☐ No change ☐ Progression ☐ Not involved ☐ Not evaluated	Unknown

Proceed to next page for Diseases Status section



Treatment Type	HCT
neument type	1101

Appendix 1 Best Response and Disease Status (Disease Specific) continued
Complete only for PCN Disease Status
Was the patient on dialysis during this follow-up period? No Yes; Started in this follow-up period: Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Did dialysis stop? No Yes; End date:// (YYYY/MM/DD) Unknown Unknown
Complete only for AL, CLL and PCN Disease Status Leukaemias (AL, CLL) and PCN (complete only for patient in CR or sCR) Minimal residual disease (MRD): Positive Increasing (>1log10 change) Stable (<1log10 change) Decreasing (>1log10 change) Unknown Negative
 Not evaluated Unknown Date MRD status evaluated:/ (YYYY/MM/DD)
Date MRD status evaluated: $/ / / / / / / / / / / / / / / / / / / $



Treatment Type	НСТ
----------------	-----

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Myeloproliferative neoplasms (MPN), Myelodysplastic neoplasms (MDS), MDS/MPN overlap syndromes

Complete remission (CR)	Number: 1st
	☐ 2nd
	Grd or higher
	Unknown
Improvement but no CR	
Primary refractory phase (no change)	
□ Relapse	Number: 1st
	☐ 2nd
	3rd or higher
	Unknown
Progression/Worsening	
☐ Not evaluated	
Unknown	



Treatment Type	П	НСТ
----------------	---	-----

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Appendix 1

Best Response and Disease Status (Disease Specific)

continued

Autoimmune disorders

□ No evidence of disease
Improved
Unchanged
U Worse
Not evaluated

Haemoglobinopathies

<u>Thalassaemia:</u>

Complete only for Thalassen	nia Best Response
Transfusion independent	Date of last transfusion: / _ / (YYYY/MM/DD) Unknown (after HCT)
Transfusions required;	Date of first transfusion://(YYYY/MM/DD) Unknown (after HCT)
☐ Not evaluated	
Unknown	

Complete or	nly for Thala	assemia Diseas	se Status
	ing for fille		

Patient requires transfusions during follow-up pe	eriod:
No No	
Yes; Return to transfusion dependence after HCT or transfusion free period;	Date of first transfusion: / / (YYYY/MM/DD) Unknown (after HCT or transfusion free period)
Ongoing transfusion dependence since previous assessment	
Number of units: Unknown (during follow-up period)	
Did transfusions stop? 🔲 No	
Yes; Date of I	ast transfusion: / / (YYYY/MM/DD) 🔲 Unknown
Unknown	
Unknown	



Treatment Type	HCT
----------------	-----

Appendix 1

Best Response and Disease Status (Disease Specific)

continued

Lymphomas

Chemorefractory relapse or progression, including primary refractory disease			
Complete remission (CR):	Confirmed	Unconfirmed (CRU*)	🔲 Unknown
Partial remission (PR)			
Stable disease (no change, no response/loss of response)			
Untreated relapse (from a previous CR) or progression (from a previous PR)			
Not evaluated			
Unknown			

* CRU: Complete response with persistent scan abnormalities of unknown significance

Solid tumours

Complete remission (CR): Confirmed Unconfirmed Unknown		
First partial remission		
Partial remission (PR)		
Progressive disease		
🗌 Relapse: 🔄 Resistant 📋 Sensitive 📋 Unknown		
Stable disease (no change, no response/loss of response)		
Not evaluated		
Unknown		

Bone marrow failures (incl. AA)

Complete remission (CR)
Partial remission (PR)
Haematological improvement (HI); NIH partial response
Stable disease (no change, no response/loss of response)
Relapse / Progression
Not evaluated
Unknown

	v failures (incl. AA) Disease Status	ì
Did transfusions stop during	Patient was never transfusion dependent	i
the follow-up period?	□ No	T T
1	Yes; Did the patient return to transfusion dependency afterwards?	Î.
	□ No	Ì
	Yes; First transfusion date: / _ / _ (YYYY/MM/DD) 🔲 Unknown	i
	(after transfusion free period)	į
	Unknown	į
1	Unknown	i
1		I I



Appendix 1	L
------------	---

Best Response and Disease Status (Disease Specific)

continued

Haemoglobinopathies

Sickle cell disease:

Complete only for Sickle cell disease Best Response

No return of sickling episodes	
Return of sickling episodes;	Date of first episode: / _ / (YYYY/MM/DD) Unknown (after HCT)
Not evaluated	
🔲 Unknown	

Complete only for Sickle cell disease Disease Status

Sickling episodes occur during follow-up period:

i i	No	
	Yes; First return of sickling episodes after Date of first episode : / _ / _ (<i>YYYY/MM/DD</i>) Unknown (after HCT)	
	Ongoing presence of sickling episodes	
	Number of SCD episodes: Unknown (during follow-up)	
 	Unknown	

Other diagnosis

No evidence of disease
No response
U Worse
□ Not evaluated

(EBMT

EBMT Centre Identification Code (CIC): ____ Hospital Unique Patient Number (UPN): _____ Patient Number in EBMT Registry: _____ Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1

Disease Status Inborn errors only

ended dataset			
atient height at this follow-up:	_ cm 🔲 Not evaluated	🔲 Unknown	
atient weight at this follow-up:	_ kg 🔲 Not evaluated	🔲 Unknown	
Patient is attending: Catient is attending: Catient is attending: Catient is not able Catient is not a			
(Only for Inborn errors of Immunity) mmune profiling done during this follow- Test date: / / (YYYY/MM/D		🗌 Yes 🔲	Unknown
		Tes	Unknown Units (for CD4 and CD8, select unit)
mmune profiling done during this follow- Test date:// (YYYY/MM/D			
nmune profiling done during this follow- Test date: / / (YYYY/MM/D Cell type and test results	D) 🗌 Unknown		Units (for CD4 and CD8, select unit)
mmune profiling done during this follow- Test date: / _ / _ (YYYY/MM/D) Cell type and test results CD3 T-cells:	D) Unknown] Unknown] Unknown	Units (for CD4 and CD8, select unit) Cells/µl
mmune profiling done during this follow- Test date: //(YYYY/MM/D) Cell type and test results CD3 T-cells:	D) Unknown	Unknown Unknown	Units (for CD4 and CD8, select unit) Cells/μl Cells/μl
nmune profiling done during this follow- Test date: // (YYYY/MM/D) Cell type and test results CD3 T-cells:	D) Unknown	Unknown Unknown Unknown	Units (for CD4 and CD8, select unit) Cells/μl Cells/μl Cells/μl
mmune profiling done during this follow- Test date: // (YYYY/MM/D) Cell type and test results CD3 T-cells:	D) Unknown] Unknown] Unknown] Unknown] Unknown	Units (for CD4 and CD8, select unit) Cells/µl Cells/µl Cells/µl Cells/µl
mmune profiling done during this follow- Test date: //(YYYY/MM/D.) Cell type and test results CD3 T-cells:	D) Unknown] Unknown] Unknown] Unknown] Unknown] Unknown	Units (for CD4 and CD8, select unit) Cells/µl Cells/µl Cells/µl Cells/µl Cells/µl
mmune profiling done during this follow- Test date: ///	D) Unknown	Unknown Unknown Unknown Unknown Unknown Unknown	Units (for CD4 and CD8, select unit) Cells/µl Cells/µl Cells/µl Cells/µl Cells/µl Cells/µl □ % of CD4 □ Cells/µl
mmune profiling done during this follow- Test date: / _ / _ (YYYY/MM/D) Cell type and test results CD3 T-cells:	D) Unknown	Unknown Unknown Unknown Unknown Unknown Unknown Unknown	Units (for CD4 and CD8, select unit) Cells/µl Cells/µl Cells/µl Cells/µl Cells/µl Cells/µl 0 % of CD4 Cells/µl 0 % of CD8 Cells/µl



Treatment Type		HCT
----------------	--	-----

Appendix 1

Disease Status

(Only for Inborn errorrs of immunity)

Extended dataset

Select the immunomodulatory treatments the patient received in the 3 months before the follow-up. Only report treatments administered in the 3 months before this follow-up. Do not report treatments for GvHD or other

HCT/CT related complications, <u>only</u> for the underlying disease

Steroids (>0.5 mg/kg/day prednison equivalent)
Cyclosporine A
🔲 Tacrolimus
Sirolimus
Ruxolitinib
Baricitinib
Other JAK-inhibitor, specify:
🔲 Leniolisib
Abatacept
🔲 Anakinra
🔲 Canakinumab
Etoposide
🔲 Interferon gamma
Etanercept
Infliximab
🔲 Vedolizumab
🔲 Dupilumab
🔲 Emapalumab
PEG-ADA
Other drug; specify:



Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1 Disease Status

Inborn errors of Immunity only

Extended dataset

Comorbidities during this follow-up period

Only for Inborn Errors of Immunity

Indicate in the table below if the comorbidities de novo, resolved, improved, stabilised or worsened during this follow-up period. No No Inflammatory bowel Crohn's disease or □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo ulcerative colitis disease Not evaluated SLE, RA, polymyositis, No No mixed CTD or Rheumatologic □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo polymyalgia rheumatica Not evaluated Serum creatinine > 2 No No mg/dL or >177 µmol/L, Renal: □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo moderate/severe on dialysis, or prior renal transplantation Not evaluated Chronic hepatitis, 🗌 No bilirubin between Upper Limit Normal □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo Hepatic: mild (ULN) and 1.5 x ULN, or AST/ALT between Not evaluated ULN and 2.5 × ULN Liver cirrhosis, □ No bilirubin greater than Hepatic: 1.5 × ULN, or □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo moderate/severe AST/ALT greater than Not evaluated 2.5 × ULN Bronchiectasis, No No interstitial Chronic lung pneumonitis, GLILD, □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo disease oxygen dependency, structural lung disease Not evaluated (e.g. pneumatoceles) No No Leukaemia, Pre-HCT lymphoma, Yes: In remission Stable disease Relapsed Not evaluated malignancy myelodysplastic syndrome (MDS) Not evaluated No No Weight <3rd percentile ☐ Yes: ☐ Resolved ☐ Improved ☐ Stabilised ☐ Worsened ☐ De novo Failure to thrive or requirement for (par)enteral feeding Not evaluated No No Any infection requiring therapy in the Active infection at Resolved Improved Stabilised Worsened Yes: HCT immediate pre HCT period Not evaluated No No I.e. splenomegaly, Lymphoproliferation organ specific □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo lymphoproliferation 🔲 Not evaluated



EBMT Centre Identification Code (CIC): ____ Hospital Unique Patient Number (UPN): _____ Patient Number in EBMT Registry: _____

Treatment Type	🗌 нст
.	

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1

Disease Status

Inborn errors only

Extended dataset

Comorbidities during this follow-up period

Only for Inborn Errors of Immunity

Indicate in the table below if the comorbidities de novo, resolved, improved, stabilised or worsened during this follow-up period.

Pre-HCT organ impairment	Infectious or non-infectious (including neurologic)	 No Yes: Resolved Not evaluated 	Improved	Stabilised	U Worsened
Autoimmunity/ autoinflammation	Pre HCT/CT (includes patients in remission but on immunomodulatory treatment within 3 months before HCT/CT)	 □ No □ Yes: □ Resolved □ Not evaluated 	Improved	Stabilised	U Worsened
as the patient admitted to ICU during this follow-up period? 🗌 No 🛛 🗌 Yes 🔲 Unknown					



Treatment Type

Appendix 2

-- Pathogens as per EBMT Registry database --

*<u>As defined by the IDSA</u> (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)

Bacterial infections

Gram-positive:

- · Clostridioides difficile
- · Enterococcus faecalis (vancomycin-susceptible)
- · Enterococcus faecalis (vancomycin-resistant)
- · Enterococcus faecium (vancomycin-susceptible)
- \cdot Enterococcus faecium (vancomycin-resistant)
- Listeria monocytogenes
- · Nocardia spp (specify)
- · Staphylococcus aureus MSSA (methicillin-susceptible)
- · Staphylococcus aureus MRSA (methicillin-resistant) vancomycin-susceptible
- · Staphylococcus aureus MRSA (methicillin-resistant) vancomycin not tested
- · Staphylococcus aureus MRSA and VISA (vancomycin-intermediate, MIC 4-8 µg/ml)
- · Staphylococcus aureus MRSA and VRSA (vancomycin-resistant, MIC \geq 16 µg/ml)
- · Staphylococcus coagulase-negative spp (at least two positive blood cultures)
- · Streptococcus pneumoniae
- · Streptococcus viridans
- · Streptococcus other spp (specify)
- · Gram-positive bacteria other spp (specify)

Gram-negative:

- Acinetobacter baumannii
- · Campylobacter jejuni
- \cdot Citrobacter freundii
- · Enterobacter cloacae
- · Enterobacter other spp (specify)
- · Escherichia coli
- · Haemophilus influenzae
- · Helicobacter pylori
- · Klebsiella aerogenes (carbapenem-susceptible)
- · Klebsiella pneumoniae (carbapenem-susceptible)
- \cdot Klebsiella (any species) (carbapenem-resistant) (specify)
- \cdot Legionella pneumophila
- Morganella morganii
- · Neisseria gonorrhoeae
- · Neisseria meningitidis
- Proteus vulgaris
- \cdot Providencia spp
- · Pseudomonas aeruginosa (carbapenem-susceptible)
- · Pseudomonas aeruginosa (carbapenem-resistant)
- · Salmonella spp (specify)
- · Serratia marcescens
- · Shigella spp
- · Stenotrophomonas maltophilia
- Treponema pallidum
- · Gram-negative bacteria other spp (specify)

Other bacteria:

- · Chlamydia spp
- · Chlamydophila
- · Mycobacterium other spp (specify)
- \cdot Mycobacterium tuberculosis
- \cdot Mycoplasma pneumoniae
- · Rickettsia spp
- \cdot Bacteria other (specify)

2025-04-29

Viral infections: · Adenovirus

· Gastrointestinal viruses:

o Norovirus

o Rotavirus

o HAV

o HBV

o HCV

o HEV

· Herpes group:

o CMV

o EBV

o HHV6

o HHV7

o HHV8

Human papilloma viruses (HPV)

o Other polyomavirus (specify)

o Respiratory virus other (specify)

o HS

o VZ

· Parvovirus

o BK

o JC

· Polyomaviruses:

o Merkel cell

· Respiratory viruses:

o Enterovirus

o Influenza A

o Influenza B

o Rhinovirus

o RSV

o Parainfluenza

o SARS-CoV-2

· Viruses other (specify)

o Human coronavirus

o Metapneumovirus

· HIV

· Hepatotropic viruses:



Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Appendix 2

-- Pathogens as per EBMT Registry database -- continued

*<u>As defined by the IDSA</u> (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)

Fungal infections:

Yeasts:

- Candida albicans
- · Candida auris
- · Candida other (specify)
- · Cryptococcus neoformans
- · Trichosporon (specify)
- Pneumocytis jiroveci
- \cdot Yeasts other (specify)

Moulds:

- · Aspergillus flavus
- · Aspergillus fumigatus
- · Aspergillus other spp (specify)
- · Aspergillus terreus
- · Fusarium other spp (specify)
- \cdot Fusarium solani
- · Lomentospora prolificans (formerly Scedosporium prolificans)
- · Order Mucorales (specify)
- · Dematiaceous fungi (Phaeohyphomycosis) (specify)
- · Scedosporium spp (specify)
- \cdot Moulds other spp (specify)
- · Mould infection diagnosed based on positive galactomannan only, without
- microbiological confirmation
- Blastomyces spp
- · Histoplasma spp (specify)
- · Coccidioides spp
- · Paracoccidioides spp

Parasitic infections:


- Protozoa:
- · Babesia spp (specify)
- · Cryptosporidium
- · Giardia spp
- · Leishmania spp (specify)
- · Plasmodium spp (specify)
- · Toxoplasma gondii
- · Trypanosoma cruzi
- · Protozoa other spp (specify)

Helminths:

- · Strongyloides stercoralis
- · Other helminths



Treatment Type	П нс
----------------	------





Non-infecti	Appendix 4 ous Complications CTCAE term No Reportin	ig Required
Non-infectious complications• Allergic reaction• All laboratory abnormalities• All types of pain• Gastritis• Alopecia• Hematologic toxiciti• Blurred vision• Hematoma• Diarrhoea (enteropathy)• Hypertension• Dry mouth• Injection site reaction• Dyspepsia• Malaise• Dysphagia• Mucositis• Edema• Sore throat	Infectious complications Minor ophthalmologic bacterial infections External otitis treated topically Otitis media treated with oral antibiotics Isolated lip herpes simplex Bacterial tonsillitis or pharyngitis treated orally 	 Vaginal candidiasis treated topically or with a single oral dose Asymptomatic bacteriuria due to a pathogen not multi-resistant Single low urinary tract infection treated orally without need for hospitalisation Phlebitis following peripheral intravascular infusion that resolved after intravascular removal without treatment with antibiotics
 Esophageal stenosis Fatigue Vertigo Flashes Weight loss 	 Bilateral cervical lymph node enlargement concurrent with URTI that resolved without specific treatment, together with the resolution of URTI Local superficial wound infection resolved under topical antibiotics (incl. impetigo) Minor skin bacterial infections Minor fungal skin infection Diaper rash treated with local antifungals Candidal balanitis treated topically 	
	Appendix 5	

-- Intravascular catheter-related infections --

CVC infections:

· Catheter colonization · Tunnel infection

Phlebitis
 Pocket infection

Exit site infection
 Bloodstream infection



Patient Number in EBMT Registry: ______

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 6 Cell Infusion Sheet Chronological number of CI episode for this patient: Date of the first infusion (within this episode): _ _ / _ / _ (YYYY/MM/DD) Not applicable for Inborn Errors Number of infusions within this episode (10 weeks): (Count only infusions that are part of the same regimen and given for the same indication.) Source of cells: Allogeneic ☐ Autologous Type of cells: Lymphocytes (DLI) ☐ Mesenchymal ☐ Fibroblasts ☐ Dendritic cells □ NK cells ☐ Regulatory T-cells ☐ Gamma/delta cells Virus-specifc T-cells; specify virus: Other; specify: ____ Not applicable for Inborn Errors Disease status at time of this cell infusion*: * Indicate the disease status corresponding to indication diagnosis by selecting from the list provided in Appendix 1 Indication: Poor graft function (check all that apply) ☐ Infection prophylaxis □ Planned/protocol Other; specify: _____ ☐ Prophylactic Treatment of acute GvHD Treatment of chronic GvHD ☐ Treatment PTLD, EBV lymphoma Treatment for primary disease ☐ Mixed chimaerism Loss/decreased donor chimaerism Treatment of viral infection other than EBV Acute GvHD -- maximum grade (after this infusion episode but before any subsequent cell infusion/HCT/CT): \square 0 (none) \Box 1 □ 2 Date Acute GvHD onset after cell infusion: ____/ __/ (YYYY/MM/DD) □ 3 Unknown Π4 □ Present but grade unknown